References:
Adhikari, S. P., Meng, S., Wu, Y.-J., Mao, Y.-P., Ye, R.-X., Wang,
Q.-Z., . . . Raat, H. (2020). Epidemiology, causes, clinical
manifestation and diagnosis, prevention and control of coronavirus
disease (COVID-19) during the early outbreak period: a scoping review.Infectious diseases of poverty, 9 (1), 1-12.
Ahmed, T., Shah, R. J., Rahim, S. E. G., Flores, M., & O’Linn, A.
(2020). Coronavirus Disease 2019 (COVID-19) Complicated by Acute
Respiratory Distress Syndrome: An Internist’s Perspective. Cureus,
12 (3).
Alharbi, N. K., Padron-Regalado, E., Thompson, C. P., Kupke, A., Wells,
D., Sloan, M. A., . . . Warimwe, G. (2017). ChAdOx1 and MVA based
vaccine candidates against MERS-CoV elicit neutralising antibodies and
cellular immune responses in mice. Vaccine, 35 (30), 3780-3788.
Anderson, R. M., Heesterbeek, H., Klinkenberg, D., & Hollingsworth, T.
D. (2020). How will country-based mitigation measures influence the
course of the COVID-19 epidemic? The Lancet, 395 (10228), 931-934.
Ang, L., Lee, H. W., Kim, A., Lee, J. A., Zhang, J., & Lee, M. S.
(2020). Herbal medicine for treatment of children diagnosed with
COVID-19: A review of guidelines. Complementary therapies in
clinical practice, 39 , 101174-101174. doi:10.1016/j.ctcp.2020.101174
Barnard, D. L., Day, C. W., Bailey, K., Heiner, M., Montgomery, R.,
Lauridsen, L., . . . Sidwell, R. W. (2006). Evaluation of
immunomodulators, interferons and known in vitro SARS-coV inhibitors for
inhibition of SARS-coV replication in BALB/c mice. Antiviral
Chemistry and Chemotherapy, 17 (5), 275-284.
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., . . . Yang, Y.
(2020). Experimental treatment with favipiravir for COVID-19: an
open-label control study. Engineering .
Chinn, I. K., Blackburn, C. C., Manley, N. R., & Sempowski, G. D.
(2012). Changes in primary lymphoid organs with aging. Paper
presented at the Seminars in immunology.
Cohen, J. (2020). Vaccine designers take first shots at COVID-19:
American Association for the Advancement of Science.
Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic.Acta bio-medica: Atenei Parmensis, 91 (1), 157-160.
Cui, J., Li, F., & Shi, Z.-L. (2019). Origin and evolution of
pathogenic coronaviruses. Nature reviews Microbiology, 17 (3),
181-192.
Desai, A., Grolleau‐Julius, A., & Yung, R. (2010). Leukocyte function
in the aging immune system. Journal of leukocyte biology, 87 (6),
1001-1009.
Devaux, C. A., Rolain, J. M., Colson, P., & Raoult, D. (2020). New
insights on the antiviral effects of chloroquine against coronavirus:
what to expect for COVID-19? Int J Antimicrob Agents, 55 (5),
105938. doi:10.1016/j.ijantimicag.2020.105938
Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat
coronavirus disease 2019 (COVID-19). Drug discoveries &
therapeutics, 14 (1), 58-60.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., . . . Hu, Y.
(2020). Effectiveness of convalescent plasma therapy in severe COVID-19
patients. Proceedings of the National Academy of Sciences,
117 (17), 9490-9496.
Garami, A. R. (2020). Preventing a covid-19 pandemic-is there a magic
bullet to save COVID-19 patients? We can give it a try. BMJ
Comments. BMJ, 368 .
Golchin, A., Seyedjafari, E., & Ardeshirylajimi, A. (2020). Mesenchymal
stem cell therapy for COVID-19: present or future. Stem Cell
Reviews and Reports , 1-7.
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A.,
. . . Lescure, F.-X. (2020). Compassionate use of remdesivir for
patients with severe Covid-19. New England Journal of Medicine .
Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin,
H.-J., . . . Yan, Y. (2020). The origin, transmission and clinical
therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on
the status. Military Medical Research, 7 (1), 1-10.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T.,
Erichsen, S., . . . Nitsche, A. (2020). SARS-CoV-2 cell entry depends on
ACE2 and TMPRSS2 and is blocked by a clinically proven protease
inhibitor. Cell .
Hofmann, H., & Pöhlmann, S. (2004). Cellular entry of the SARS
coronavirus. Trends in microbiology, 12 (10), 466-472.
Jawhara, S. (2020). Could Intravenous immunoglobulin collected from
recovered coronavirus patients protect against COVID-19 and strengthen
the immune system of new patients? International journal of
molecular sciences, 21 (7), 2272.
Kalkeri, R., Goebel, S., & Sharma, G. D. (2020). SARS-CoV-2 Shedding
from Asymptomatic Patients: Contribution of Potential Extrapulmonary
Tissue Reservoirs. The American Journal of Tropical Medicine and
Hygiene , tpmd200279.
Kirkwood, A. (2019). The reality of virtual pharmaceutical companies.Drug Discovery , 11.
Klopfenstein, T., N’dri Juliette Kadiane-Oussou, P., Royer, Y., Toko,
L., Gendrin, V., & Zayet, S. (2020). Diarrhea: an underestimated
symptom in coronavirus disease 2019. Clinics and Research in
Hepatology and Gastroenterology .
Luo, H., Tang, Q.-l., Shang, Y.-x., Liang, S.-b., Yang, M., Robinson,
N., & Liu, J.-p. (2020). Can Chinese medicine be used for prevention of
corona virus disease 2019 (COVID-19)? A review of historical classics,
research evidence and current prevention programs. Chinese journal
of integrative medicine , 1-8.
Menni, C., Valdes, A., Freydin, M. B., Ganesh, S., Moustafa, J. E.-S.,
Visconti, A., . . . Falchi, M. (2020). Loss of smell and taste in
combination with other symptoms is a strong predictor of COVID-19
infection. MedRxiv .
Nikolich-Žugich, J. (2018). The twilight of immunity: emerging concepts
in aging of the immune system. Nature immunology, 19 (1), 10-19.
Nikolich-Zugich, J., Knox, K. S., Rios, C. T., Natt, B., Bhattacharya,
D., & Fain, M. J. (2020). SARS-CoV-2 and COVID-19 in older adults: what
we may expect regarding pathogenesis, immune responses, and outcomes.GeroScience , 1-10.
Philippidis, A. (2020). COVID-19: Top 60 Drug Treatments in Development:
The biopharma industry is ramping up the development of dozens of
potential drug therapies and clinical testing in an all-hands effort to
combat the pandemic. Genetic Engineering & Biotechnology News,
40 (4), 10-13.
Principi, N., & Esposito, S. (2020). Chloroquine or hydroxychloroquine
for prophylaxis of COVID-19. The Lancet Infectious Diseases .
Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B.,
Ogino, M., . . . Shekar, K. (2020). Planning and provision of ECMO
services for severe ARDS during the COVID-19 pandemic and other
outbreaks of emerging infectious diseases. The Lancet. Respiratory
medicine, 8 (5), 518-526. doi:10.1016/S2213-2600(20)30121-1
Runfeng, L., Yunlong, H., Jicheng, H., Weiqi, P., Qinhai, M., Yongxia,
S., . . . Zifeng, Y. (2020). Lianhuaqingwen exerts anti-viral and
anti-inflammatory activity against novel coronavirus (SARS-CoV-2).Pharmacological research, 156 , 104761.
doi:10.1016/j.phrs.2020.104761
Shanmugaraj, B., Siriwattananon, K., Wangkanont, K., & Phoolcharoen, W.
(2020). Perspectives on monoclonal antibody therapy as potential
therapeutic intervention for Coronavirus disease-19 (COVID-19).Asian Pac J Allergy Immunol, 38 (1), 10-18.
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020).
COVID-19 infection: origin, transmission, and characteristics of human
coronaviruses. Journal of Advanced Research .
Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., . . .
Melino, G. (2020). COVID-19 infection: the perspectives on immune
responses: Nature Publishing Group.
Shin, J. S., Jung, E., Kim, M., Baric, R. S., & Go, Y. Y. (2018).
Saracatinib inhibits middle east respiratory syndrome-coronavirus
replication in vitro. Viruses, 10 (6), 283.
Shirato, K., Kawase, M., & Matsuyama, S. (2018). Wild-type human
coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for
cell entry. Virology, 517 , 9-15.
Stower, H. (2020). Lopinavir–ritonavir in severe COVID-19. Nature
Medicine, 26 (4), 465-465.
Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C., Zhou, J., . . . Gao, G.
F. (2016). Epidemiology, genetic recombination, and pathogenesis of
coronaviruses. Trends in microbiology, 24 (6), 490-502.
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P.
E., Ksiazek, T. G., . . . Nichol, S. T. (2005). Chloroquine is a potent
inhibitor of SARS coronavirus infection and spread. Virology
journal, 2 (1), 69.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., . . . Xiao, G.
(2020). Remdesivir and chloroquine effectively inhibit the recently
emerged novel coronavirus (2019-nCoV) in vitro. Cell research,
30 (3), 269-271.
Xie, M., & Chen, Q. (2020). Insight into 2019 novel coronavirus—an
updated intrim review and lessons from SARS-CoV and MERS-CoV.International Journal of Infectious Diseases .
Yang, Y., Islam, M. S., Wang, J., Li, Y., & Chen, X. (2020).
Traditional Chinese medicine in the treatment of patients infected with
2019-new coronavirus (SARS-CoV-2): a review and perspective.International journal of biological sciences, 16 (10), 1708.
Yang, Y., Lu, Q., Liu, M., Wang, Y., Zhang, A., Jalali, N., . . . Xu, B.
(2020). Epidemiological and clinical features of the 2019 novel
coronavirus outbreak in China. MedRxiv .
Zhang, Q., Wang, Y., Qi, C., Shen, L., & Li, J. (2020). Clinical trial
analysis of 2019‐nCoV therapy registered in China. Journal of
medical virology, 92 (6), 540-545.
Zhong, N., Zheng, B., Li, Y., Poon, L., Xie, Z., Chan, K., . . . Xie, J.
(2003). Epidemiology and cause of severe acute respiratory syndrome
(SARS) in Guangdong, People’s Republic of China, in February, 2003.The Lancet, 362 (9393), 1353-1358.
Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., &
Zhang, L. J. (2020). Coronavirus disease 2019 (COVID-19): a perspective
from China. Radiology , 200490.